Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Anticancer drug targets: cell cycle and checkpoint control
Geoffrey I. Shapiro, J. Wade Harper
Geoffrey I. Shapiro, J. Wade Harper
View: Text | PDF
Perspective

Anticancer drug targets: cell cycle and checkpoint control

  • Text
  • PDF
Abstract

Authors

Geoffrey I. Shapiro, J. Wade Harper

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
G2/M checkpoint control. DNA damage induces the ATM-mediated phosphoryla...
G2/M checkpoint control. DNA damage induces the ATM-mediated phosphorylation of chk2 as well as phosphorylation of chk1, both of which phosphorylate cdc25C, promoting its interaction with 14-3-3 proteins and its cytoplasmic sequestration. As a consequence, cdc25C cannot dephosphorylate cdc2, which remains in an inactive state, resulting in G2 arrest. p53 is also activated following DNA damage, inducing both 14-3-3ς and p21Waf1/Cip1, both of which are important in the maintenance of cdc2 inhibition and G2 arrest. In cells lacking p53, disruption of cdc25C cytoplasmic sequestration facilitates mitotic entrance of damaged cells, resulting in cell death. Therefore, caffeine, which inhibits ATM-mediated kinase activity, and UCN-01, which targets chk1, limit phosphorylation of cdc25C, allowing activation of cdc2 and mitotic entry and selectively sensitizing p53-deficient cells to DNA-damaging agents. ATM contributes to p53 phosphorylation following DNA damage. This phosphorylation event is inhibited by high doses of caffeine, perhaps explaining why, at high caffeine concentration, some sensitization to DNA damage is also observed in cells expressing wild-type p53, although effects are still more pronounced in cells lacking p53. Low doses of caffeine specifically sensitize p53-deficient cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts